A company that's taking a new approach to tackling Alzheimer's is moving into human trials after raising $133 million

AP/Alastair Grant

• Biotech startup Alector is getting ready to put its first batch of neurodegenerative drugs into humans after raising an additional $133 million. 
• Alector is developing treatments that harness the body's immune system to tackle conditions like Alzheimer's, and other forms of dementia.
• The plan is to get two drugs into clinical trials in the next few months, with a third starting in early 2019. 

---

Alector, a startup that's trying to harness the body's immune system to treat neurologic diseases like Alzheimer's just raised another $133 million to get its first batch of drugs into human trials. 

The approach of using the body's immune system to treat a particular disease has so far proven successful in the field of cancer, where it's known as immuno-oncology. It's led to remarkable remissions in some patients, along with some first-of-its kind approvals. San Francisco-based Alector is hoping to have similar success in building out the field of "immuno-neurology."

See the rest of the story at Business Insider

NOW WATCH: The man that won the Nobel Prize in economics for contract theory shares his thoughts on smart contracts

See Also:

• Here's what it's like to visit Whittier, Alaska — the 'town under one roof'
• A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just got approved
• The FDA just approved a new cancer drug that’s part of a groundbreaking approach to tackling the disease

SEE ALSO: A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just got approved

DON'T MISS: The billion-dollar healthcare unicorns you should be watching in 2018

from Business Insider https://ift.tt/2JUbn7P